Stuttgart:OJU1

Oramed Letter to Shareholders

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Senior, Letter, Joint venture, Investment, Marketing, FDA, Hemorrhoid, Note, Herpes labialis, Wart, JV, BMI, License, Patient, Pruritus ani, Anal, Body mass index, Failure, Glycated hemoglobin, Partnership, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.
  • I am pleased to share with you an update regarding Oramed.
  • Oramed and HTIT Joint Venture:
    In January 2024, Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture ("JV"), centered around Oramed's cutting-edge oral drug delivery technology.
  • We thank you for your support and look forward to keeping our shareholders updated on the important milestones ahead.

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
Oramed, POD, TASE, Technology, Diabetes, Conference, Nasdaq, Company, Pharmaceutical industry

NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview and share the Company's latest updates at the H.C. Wainwright 24th Annual Global Investment Conference, on September 13, 2022 in New York, NY.

Key Points: 
  • NEW YORK, Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview and share the Company's latest updates at the H.C. Wainwright 24th Annual Global Investment Conference, on September 13, 2022 in New York, NY.
  • The presentation will be viewable starting Tuesday, September 13, 2022, at 3:00 p.m. Eastern time, and will be available for 90 days, through the following link: https://journey.ct.events/view/fbd3fb46-d695-4516-9e06-8d9247a157ab .
  • Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology.

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

Retrieved on: 
Monday, July 11, 2022
Company, Oramed, Conference, TASE, Canaccord Genuity, Nasdaq, POD, Technology, Diabetes, Pharmaceutical industry

The link to view the presentation will be uploaded to the Oramed website ( www.oramed.com ) 48 hours before the event and will be available for 90 days following the presentation.

Key Points: 
  • The link to view the presentation will be uploaded to the Oramed website ( www.oramed.com ) 48 hours before the event and will be available for 90 days following the presentation.
  • Oramed Pharmaceuticals (Nasdaq/TASE: ORMP)is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Established in 2006, with offices inthe United StatesandIsrael, Oramed has developed a novel Protein Oral Delivery (POD) technology.
  • In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule.

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

Retrieved on: 
Wednesday, June 1, 2022
UCLA, CVS Caremark, Pritzker School, Research, Cedars-Sinai Medical Center, Biotechnology, Knowledge, Keck School of Medicine of USC, USC, ADA, Pressure, Legislation, Forward-looking statement, Coronavirus Scientific Advisory Board (Turkey), Security (finance), Guideline, U.S. Securities and Exchange Commission, Diabetes, Public service, Nasdaq, University, TASE, Method, FDA, Endocrinology, POD, Technology, Book, MD, Bernardo Houssay Award, Stanford University, Pritzker School of Medicine, Chicago (franchise), Pharmaceutical industry, Medicine, Oramed, Exercise

NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.

Key Points: 
  • NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.
  • Anne Peters, MD, is Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs.
  • "We are excited to welcome Anne as a new member of Oramed's Scientific Advisory Board.
  • "I am honored to be joining the Scientific Advisory Board of Oramed Pharmaceuticals.

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

Retrieved on: 
Tuesday, May 24, 2022
Diabetes, Composition, Knowledge, Company, Patent, U.S. Securities and Exchange Commission, POD, Nasdaq, Method, TASE, Legislation, Research, Biotechnology, Pressure, Forward-looking statement, Technology, Insulin, Security (finance), C-peptide, Pharmaceutical industry, Oramed

The patent addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).

Key Points: 
  • The patent addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
  • Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection.
  • Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology.
  • For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes.

Oramed to Present at H.C. Wainwright Global Investment Conference

Retrieved on: 
Wednesday, May 18, 2022
Diabetes, Knowledge, U.S. Securities and Exchange Commission, Nasdaq, TASE, Legislation, Research, Method, Conference, Biotechnology, Pressure, Forward-looking statement, Technology, Security (finance), POD, Pharmaceutical industry, Oramed

NEW YORK, May 18, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview at the H.C. Wainwright Global Investment Conference, on May 25, 2022 in Miami, Florida.

Key Points: 
  • NEW YORK, May 18, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview at the H.C. Wainwright Global Investment Conference, on May 25, 2022 in Miami, Florida.
  • Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology.
  • In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule ( ORMD-0901 ).
  • For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed' s reports filed from time to time with the Securities and Exchange Commission.

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Retrieved on: 
Tuesday, May 3, 2022
TASE, Hypoglycemia, U.S. Securities and Exchange Commission, Forward-looking statement, A1C, NASDAQ, Biotechnology, Food and Drug Administration, Plasma, T2D, Food, Legislation, Patient, POD, Security (finance), Clinical trial, FDA, Diabetes, Knowledge, Weight gain, Pressure, Fasting, Method, ORA, Technology, Research, Pharmaceutical industry, Oramed

"We are thrilled to announce that the world's first Phase 3 oral insulin study, conducted under an FDA protocol, has achieved a significant milestone with the completion of enrollment.

Key Points: 
  • "We are thrilled to announce that the world's first Phase 3 oral insulin study, conducted under an FDA protocol, has achieved a significant milestone with the completion of enrollment.
  • Following the last patient's six months of treatment, we anticipate announcing topline results in January 2023," said Oramed CEO Nadav Kidron.
  • "We are very excited about the prospect of an oral insulin option for people living with diabetes.
  • The ORA-D-013-1 study initially aimed to enroll 675 patients and has now completed its enrollment oversubscribed with a total of 710 patients.

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Retrieved on: 
Tuesday, May 3, 2022
TASE, Hypoglycemia, U.S. Securities and Exchange Commission, Forward-looking statement, A1C, NASDAQ, Biotechnology, Food and Drug Administration, Plasma, T2D, Food, Legislation, Patient, POD, Security (finance), Clinical trial, FDA, Diabetes, Knowledge, Weight gain, Pressure, Fasting, Method, ORA, Technology, Research, Pharmaceutical industry, Oramed

"We are thrilled to announce that the world's first Phase 3 oral insulin study, conducted under an FDA protocol, has achieved a significant milestone with the completion of enrollment.

Key Points: 
  • "We are thrilled to announce that the world's first Phase 3 oral insulin study, conducted under an FDA protocol, has achieved a significant milestone with the completion of enrollment.
  • Following the last patient's six months of treatment, we anticipate announcing topline results in January 2023," said Oramed CEO Nadav Kidron.
  • "We are very excited about the prospect of an oral insulin option for people living with diabetes.
  • The ORA-D-013-1 study initially aimed to enroll 675 patients and has now completed its enrollment oversubscribed with a total of 710 patients.

Oramed Appoints Yadin Rozov to its Board of Directors

Retrieved on: 
Monday, April 4, 2022
Method, Company, Master of Science, Partner, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Financial Guaranty Insurance Company, Forward-looking statement, Data science, Legislation, Board, Nasdaq, Moelis & Company, Research, Biotechnology, Columbia University, Pressure, UBS, U.S. Securities and Exchange Commission, Board of directors, Technology, Knowledge, Diabetes, GoldenTree Asset Management, Physics, POD, International Financial Institution Advisory Commission, UBS AG, Rutgers University, Engineering, Security (finance), Pharmaceutical industry, Oramed

NEW YORK, April 4, 2022 /PRNewswire/ --Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022.

Key Points: 
  • NEW YORK, April 4, 2022 /PRNewswire/ --Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022.
  • The Board determined that Mr. Rozov qualifies as an independent director under the listing rules of the Nasdaq Capital Market.
  • Before Moelis, Mr. Rozov was a Managing Director at UBS AG, where he was the Head of the Americas for the Repositioning Group.
  • For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed' s reports filed from time to time with the Securities and Exchange Commission.

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

Retrieved on: 
Tuesday, March 29, 2022
TASE, Hypoglycemia, Method, Type 2, NASDAQ, Forward-looking statement, Legislation, Physician, Needle, Research, Biotechnology, Pressure, Achievement, American Association of Clinical Endocrinologists, Industry, Technology, Knowledge, Diabetes, Type 2 diabetes, Nasdaq, U.S. Securities and Exchange Commission, POD, Weight gain, Patient, Pharmaceutical industry, IQVIA, Oramed

The survey included 88 Endocrinologists and 82 Primary Care Physicians in the U.S. and Europe.

Key Points: 
  • The survey included 88 Endocrinologists and 82 Primary Care Physicians in the U.S. and Europe.
  • Overall, health care providers were receptive to prescribing oral insulin, if approved, and the sentiment for ORMD-0801 was very positive.
  • Some potential benefits expressed by the physicians include less possibility of hypoglycemia or weight gain and the benefit of not using needles.
  • We are excited as this could be the world's first oral insulin capsule using our proprietary platform oral delivery technology."